Abstract: A plasma-facing component of a fusion reactor divertor, including an inner target transition support and a dome transition support which are integrated into an inner target-dome transition support. The inner target-dome transition support and an outer horizontal target transition support are each prepared from two materials. The channel connection inside the inner target-dome transition support and the outer horizontal target transition support is realized through an S-shaped flow channel and a collector box. In V-shaped regions of inner and outer targets, a plasma-facing unit is connected to the collector box in the transition support via a bending tube, and is communicated with a coolant flowing through horizontal and vertical targets through an intermediate flow channel in the transition block. A method of preparing the plasma-facing component is further provided.

Abstract: Provided is an illumination device comprising a support structure and a light-emitting component being provided on one side of the support structure. The support structure also has an opening on one of its sides and an optical component cooperating with the opening to form an accommodating space. The illumination device also comprises an integrally formed light transmission portion provided above a light-emitting side of the light-emitting component. The light transmission portion is configured to transmit light from the light-emitting component. The illumination device additionally comprises a plurality of sealing portions being integrally formed.

Abstract: Disclosed are a polyethylene glycol conjugate drug, and a preparation method therefor and the use thereof. Specifically, the present invention relates to a polyethylene glycol conjugate drug represented by formula A or a pharmaceutically acceptable salt thereof, a method for preparing the polyethylene glycol conjugate drug or the pharmaceutically acceptable salt thereof, an intermediate for preparing the polyethylene glycol conjugate drug or the pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the polyethylene glycol conjugate drug or the pharmaceutically acceptable salt thereof, and the use of the polyethylene glycol conjugate drug or the pharmaceutically acceptable salt thereof in the preparation of a drug.

Abstract: Logo candidates for a specific ISO data can be identified from external resources based on the enriched merchant data. Low quality images of the logo candidates are filtered out with image analysis including entropy ratio evaluations of the logo candidates. Also, the logo candidates are processed with high quality filtering including classification of the logo candidates with a deep learning classifier for distinguishing logos from non-logos. A logo from the logo candidates is selected to associate with the ISO data packets. A display having the selected logo associated with a transaction of the ISO data packets can be generated for display to users.

Abstract: Methods, systems, and computer program products for low-resource entity resolution with transfer learning are provided herein. A computer-implemented method includes processing input data via a first entity resolution model, wherein the input data comprise labeled input data and unlabeled input data; identifying one or more portions of the unlabeled input data to be used in training a neural network entity resolution model, wherein said identifying comprises applying one or more active learning algorithms to the first entity resolution model; training, using (i) the one or more portions of the unlabeled input data and (ii) one or more deep learning techniques, the neural network entity resolution model; and performing one or more entity resolution tasks by applying the trained neural network entity resolution model to one or more datasets.

Abstract: In one aspect, a method of granting geographic-based access authorization, includes storing, with a first processor, an access credential, receiving, with the first processor, travel data for at least one travel plan for a user of the access credential, transmitting, with the first processor, the received travel data to an issuer of the access credential, updating, with a second processor, access rules based on the received travel plans, receiving, by the second processor from the first processor, an access request during travel, authorizing, by the second processor, access to the first processor in accordance with the updated access rules.

Abstract: A computer-implemented method according to one embodiment includes receiving a question in a natural language format; deriving a plurality of subqueries from the question; determining that a first subquery of the plurality of subqueries cannot be resolved utilizing a curated knowledge base; resolving the first subquery, utilizing unstructured text; and adjusting the curated knowledge base, utilizing the resolved first subquery.

Abstract: Disclosed is an antigen peptide with an infectious bronchitis virus (IBV)-specific neutralizing epitope, in which the peptide is a cyclic polypeptide, and the amino acid sequence of the peptide is CSCPYVSYGRFCIQPDGSIKQC. Also disclosed are an IBV specific antibody and a preparation method thereof. Further disclosed is an ELISA method as an alternative to the neutralization potency assay. The disclosure also discloses an ELISA detection kit, and using the established pELISA method to detect IBV antibodies, it is found that the method is positively correlated with anti-IBV neutralizing antibodies, which may be used to evaluate the immune effect of IBV vaccines on IBV infected chickens and to determine the antibody level, thereby benefiting the health management of chicken flocks.

Abstract: A polyethylene glycol conjugate drug synergist, a preparation method therefor, and use thereof, specifically relating to a polyethylene glycol conjugate drug synergist as shown in formula I or a pharmaceutically acceptable salt thereof, a preparation method for the polyethylene glycol conjugate drug synergist or the pharmaceutically acceptable salt thereof, an intermediate for preparing the polyethylent glycol conjugate drug synergist or the pharmaceutically acceptable salt thereof, a composition containing the polyethylene glycol conjugate drug synergist or the pharmaceutically acceptable salt thereof, and use of the polyethylene glycol conjugate drug synergist or the pharmaceutically acceptable salt thereof in preparation of a drug.

Abstract: A method for operating a device includes the following, performed by a processing unit of the device: receiving a message signaling an incoming phone call from a calling party via a server; generating a ringing message including at least one additional parameter specifying an enriched ring-back tone to be played, as a function of at least a status information available to the device; and transmitting the ringing message to the server for playing to the calling party the enriched ring-back tone.

Abstract: A composition is provided. The composition is a water-in-oil emulsion comprising an aqueous phase and an oil phase. The aqueous phase comprises water, one or more humectants, one or more preservatives, one or more preservative boosters, one or more stabilizers and/or one or more pH adjusters. The oil phase comprises one or more solvents, one or more emulsifiers, one or more emollients and/or one or more aesthetic modifiers. Methods of preparing the composition and methods of improving the appearance of skin are also provided.

Abstract: The present disclosure provides a recombinant herpesvirus of turkeys (HVT) and a preparation method and use thereof. The present disclosure specifically provides a recombinant HVT, where an exogenous gene is inserted in a spacer region between an HVT005 region and an HVT006 region of an HVT genome; and the exogenous gene is selected from a gene derived from the group consisting of a Newcastle disease virus (NDV), an avian influenza virus (AIV), and an infectious bursal disease virus (IBDV); the spacer region between an HVT005 region and an HVT006 region of an HVT genome is located between 8,867 nt and 9,319 nt of the HVT genome, and has a nucleotide sequence set forth in SEQ ID NO: 1.

Abstract: A medical bed horizontal driving mechanism includes a bracket, a drum, an electric motor, and a position sensor. The bracket is configured to be fixedly connected to a bed frame of a medical bed. The drum is rotatably connected to the bracket. The drum is rotatable to drive a bed board of the medical bed to move relative to the bed frame. The electric motor is arranged in a cavity of the drum. A housing of the electric motor is fixedly connected to the bracket. An output shaft of the electric motor is connected to the drum to drive the drum to rotate relative to the bracket. The position sensor is arranged in the cavity of the drum. The position sensor can detect a rotational position of the drum and generate a position signal, which is used to control the electric motor.

Abstract: A cloud data center tenant-level outbound rate limiting method includes: starting a timer, receiving and generating statistics of outbound packets of tenants in a current period, obtaining local traffic rate information of the tenants based on all the outbound packets of the tenants in the current period, and generating local bandwidth demand frames of the tenants based on the local traffic rate information of the tenants; when a timing of the timer reaches the end of the current period, sending the local bandwidth demand frames of the tenants to a switch; receiving a global bandwidth demand frame sent by the switch, and computing bandwidth budgets of the tenants based on the local traffic rate information of the tenants and the global bandwidth demand frames of the tenants; modifying rate limiting parameters, and limiting the rate of the outbound packets of the tenants in a next period.

Abstract: Methods, systems, and computer program products for learning models for entity resolution using active learning are provided herein. A computer-implemented method includes determining a set of data items related to a task associated with structured knowledge base creation, and outputting the set of data items to a user for labeling. Such a method also includes generating, based on a user-labeled version of the set of data items, a candidate model for executing the task, and one or more generalized versions of the candidate model. Additionally, such a method can also include generating a final model based on one or more iterations of analysis of the candidate model and analysis of the one or more generalized versions of the candidate model, and performing the task by executing the final model on one or more datasets.

Abstract: Aspects and embodiments provide an MRI scanner-compatible virtual reality system comprising: user equipment locatable within an MRI scanner bore, the user equipment being configured to provide a subject with an immersive virtual environment; the system further comprising: at least one sensor configured to track eye movement of the subject; wherein interaction of the subject with the immersive virtual environment is controlled by the tracked eye movement. Aspects and embodiments may be implemented in a manner which recognises that VR techniques, which typically rely upon dynamic movement of a VR subject, can be used to aid with maintenance of minimal motion of a subject to be placed within an MRI scanner bore. Implementations may be such that calmness of a subject can be increased and awareness of their physical surroundings diminished, thus allowing for successful MRI image acquisition whilst seeking to minimise distress, boredom and/or frustration experienced by the subject under study.

Abstract: A method for improving skin comprising reducing the barrier function of skin, and applying a skin treatment composition to the skin. The skin treatment composition may include about 0.1 to about 25 wt. % of acetyl trifluoromethylphenyl valylglycine; about 0.5 to about 30 wt. % of a polyol; about 0.1 to about 30 wt. % of a silicone, fatty compound, or a mixtures thereof, wherein the skin treatment composition is an emulsion, and all weight percentages are based on the total weight of the skin treatment composition.

Abstract: A method for managing skin tone comprising reducing the synthesis of melanin by applying a skin treatment composition to skin. The skin treatment composition may include about 0.1 to about 25 wt. % of acetyl trifluoromethylphenyl valylglycine; about 0.5 to about 30 wt. % of a polyol; about 0.1 to about 30 wt. % of a silicone, fatty compound, or a mixtures thereof, wherein the skin treatment composition is an emulsion, and all weight percentages are based on the total weight of the skin treatment composition.

Abstract: A multilayered bullet resistant member, including a three-layered structure formed of a metal-ceramic crack arrest reflecting layer, a fiber-elastomer composite energy absorbing layer and a two-dimensional fabric blunt trauma protective layer sequentially overlapped with each other. The integration of performances of all the components guarantees high strength, hardness and good impact toughness of the bullet resistant member.